Cubist Systematic Strategies’s Revolution Medicines RVMD Stock Holding History

Cubist Systematic Strategies’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-11,326	Closed	-$514K	–	3493
2024 Q3	$514K	Buy	+11,326	New	+$493K	﹤0.01%	2195
2023 Q4	–	Sell	-63,475	Closed	-$1.76M	–	4037
2023 Q3	$1.76M	Buy	+63,475	New	+$1.88M	0.01%	1461
2023 Q1	–	Sell	-22,546	Closed	-$537K	–	4350
2022 Q4	$537K	Sell	22,546 -14,337	-39%	-$305K	﹤0.01%	2970
2022 Q3	$727K	Sell	36,883 -55,955	-60%	-$1.23M	﹤0.01%	2887
2022 Q2	$1.81M	Buy	92,838 +48,292	+108%	+$940K	0.01%	1964
2022 Q1	$1.14M	Sell	44,546 -25,537	-36%	-$556K	0.01%	1934
2021 Q4	$1.76M	Buy	70,083 +37,873	+118%	+$1.07M	0.02%	1482
2021 Q3	$886K	Sell	32,210 -43,896	-58%	-$1.28M	0.01%	1619
2021 Q2	$2.42M	Buy	76,106 +42,415	+126%	+$1.48M	0.03%	969
2021 Q1	$1.55M	Buy	+33,691	New	+$1.51M	0.02%	1224

Other funds holding RVMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cubist Systematic Strategies's RVMD Position: Q4 2024 in Review

Cubist Systematic Strategies sold out of Revolution Medicines (RVMD) in Q4 2024, closing a stake of 11,326 shares — an estimated $514K sold.

Cubist Systematic Strategies first reported a position in RVMD in Q1 2021 and held it in 10 quarters. The position peaked at $2.42M in Q2 2021. 281 funds tracked by Wall St. Rank hold RVMD as of Q4 2024.

Cubist Systematic Strategies reported no remaining Revolution Medicines position as of Q4 2024 after selling out during the quarter.
Cubist Systematic Strategies sold 11,326 Revolution Medicines shares in Q4 2024, an estimated $514K.
Cubist Systematic Strategies first reported a position in Revolution Medicines in Q1 2021 and held it in 10 quarters.
Cubist Systematic Strategies's Revolution Medicines position peaked at $2.42M in Q2 2021.
281 funds tracked by Wall St. Rank held Revolution Medicines as of Q4 2024.

Based on Cubist Systematic Strategies's 13F filing for Q4 2024, filed 14 Feb 2025.